402. Randomized Phase II Trial of Post-Operative Adjuvant Chemotherapy ±FANG™ Autologous Tumor Cell Vaccine in Colorectal Carcinoma with Liver Metastases

Molecular Therapy ◽

10.1016/s1525-0016(16)34737-2 ◽

2013 ◽

Vol 21 ◽

pp. S155

Keyword(s):

Adjuvant Chemotherapy ◽

Colorectal Carcinoma ◽

Phase Ii Trial ◽

Cell Vaccine ◽

Autologous Tumor Cell ◽

Autologous Tumor ◽

Tumor Cell Vaccine ◽

Randomized Phase Ii ◽

Autologous Tumor Cell Vaccine

Download Full-text

187. Randomized Phase II Trial of Post-Operative Adjuvant Chemotherapy ±FANG™ Autologous Tumor Cell Vaccine in Colorectal Carcinoma with Liver Metastases

Molecular Therapy ◽

10.1016/s1525-0016(16)35991-3 ◽

2012 ◽

Vol 20 ◽

pp. S74

Keyword(s):

Adjuvant Chemotherapy ◽

Colorectal Carcinoma ◽

Phase Ii Trial ◽

Cell Vaccine ◽

Autologous Tumor Cell ◽

Autologous Tumor ◽

Tumor Cell Vaccine ◽

Randomized Phase Ii ◽

Autologous Tumor Cell Vaccine

Download Full-text

Randomized phase II trial of maintenance autologous tumor cell vaccine (FANG™) following clinical complete response (cCR) in stage III/IV ovarian cancer: Preliminary results

Gynecologic Oncology ◽

10.1016/j.ygyno.2015.01.003 ◽

2015 ◽

Vol 137 ◽

pp. 2-3 ◽

Author(s):

J. Oh ◽

M. Barve ◽

E.A. Grosen ◽

B.A. Fine ◽

T.P. Heffernan ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase Ii Trial ◽

Complete Response ◽

Cell Vaccine ◽

Autologous Tumor Cell ◽

Autologous Tumor ◽

Tumor Cell Vaccine ◽

Randomized Phase Ii ◽

Autologous Tumor Cell Vaccine

Download Full-text

624. Randomized Phase II Trial of Adjuvant Autologous Tumor Cell Vaccine (FANG™) for High Risk Stage III/IV Ovarian Cancer: Preliminary Results

Molecular Therapy ◽

10.1016/s1525-0016(16)35637-4 ◽

2014 ◽

Vol 22 ◽

pp. S241-S242

Keyword(s):

Ovarian Cancer ◽

High Risk ◽

Phase Ii Trial ◽

Cell Vaccine ◽

Autologous Tumor Cell ◽

Autologous Tumor ◽

Tumor Cell Vaccine ◽

Randomized Phase Ii ◽

Autologous Tumor Cell Vaccine

Download Full-text

503. Randomized Phase II Trial of Adjuvant Autologous Tumor Cell Vaccine (FANG™) for High Risk Stage III/IV Ovarian Cancer: Preliminary Results

Molecular Therapy ◽

10.1016/s1525-0016(16)34838-9 ◽

2013 ◽

Vol 21 ◽

pp. S194-S195

Keyword(s):

Ovarian Cancer ◽

High Risk ◽

Phase Ii Trial ◽

Cell Vaccine ◽

Autologous Tumor Cell ◽

Autologous Tumor ◽

Tumor Cell Vaccine ◽

Randomized Phase Ii ◽

Autologous Tumor Cell Vaccine

Download Full-text

999 Newcastle disease virus infected intact autologous tumor cell vaccine for adjuvant active specific immunotherapy of resected colorectal carcinoma

European Journal of Cancer ◽

10.1016/0959-8049(95)96247-b ◽

1995 ◽

Vol 31 ◽

pp. S208 ◽

Author(s):

V. Schirrmacher ◽

D. Ockert ◽

E. Hagmüller ◽

H.D. Saeger

Keyword(s):

Colorectal Carcinoma ◽

Newcastle Disease Virus ◽

Newcastle Disease ◽

Specific Immunotherapy ◽

Cell Vaccine ◽

Autologous Tumor Cell ◽

Autologous Tumor ◽

Tumor Cell Vaccine ◽

Autologous Tumor Cell Vaccine

Download Full-text

Phase II Trial of B7-1 (CD-86) Transduced, Cultured Autologous Tumor Cell Vaccine Plus Subcutaneous Interleukin-2 for Treatment of Stage IV Renal Cell Carcinoma

Journal of Immunotherapy ◽

10.1097/cji.0b013e31815ba792 ◽

2008 ◽

Vol 31 (1) ◽

pp. 72-80 ◽

Author(s):

Mayer Fishman ◽

Terri B. Hunter ◽

Hatem Soliman ◽

Patricia Thompson ◽

Mary Dunn ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Phase Ii Trial ◽

Interleukin 2 ◽

Stage Iv ◽

Cell Vaccine ◽

Autologous Tumor Cell ◽

Autologous Tumor ◽

Tumor Cell Vaccine ◽

Autologous Tumor Cell Vaccine

Download Full-text

Anti-metastatic activity of hapten-modified autologous tumor cell vaccine in an animal tumor model

Cancer Immunology Immunotherapy ◽

10.1007/s00262-002-0271-9 ◽

2002 ◽

Vol 51 (4) ◽

pp. 200-208 ◽

Author(s):

Dorothy K. Sojka, Diana Felnerova, Margalit

Keyword(s):

Tumor Model ◽

Cell Vaccine ◽

Autologous Tumor Cell ◽

Autologous Tumor ◽

Tumor Cell Vaccine ◽

Animal Tumor ◽

Metastatic Activity ◽

Autologous Tumor Cell Vaccine

Download Full-text

Phase II study of B7–1 gene-modified autologous tumor cell vaccine and subcutaneous IL-2 for patients with stage IV renal cell carcinoma (RCC)

Journal of Clinical Oncology ◽

10.1200/jco.2005.23.16_suppl.4502 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. 4502-4502 ◽

Author(s):

P. Thompson ◽

M. Fishman ◽

J. Seigne ◽

M. Dunn ◽

W. Janssen ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Phase Ii Study ◽

Stage Iv ◽

Cell Vaccine ◽

Autologous Tumor Cell ◽

Autologous Tumor ◽

Tumor Cell Vaccine ◽

Autologous Tumor Cell Vaccine

Download Full-text

241. TAG Vaccine: Autologous Tumor Cell Vaccine Genetically Modified To Express GM-CSF and Block Expression of TGFbeta2 – Preclinical Development, Manufacturing and Early Clinical Data

Molecular Therapy ◽

10.1016/s1525-0016(16)39644-7 ◽

2008 ◽

Vol 16 ◽

pp. S91

Keyword(s):

Clinical Data ◽

Genetically Modified ◽

Cell Vaccine ◽

Autologous Tumor Cell ◽

Autologous Tumor ◽

Tumor Cell Vaccine ◽

Preclinical Development ◽

Gm Csf ◽

Autologous Tumor Cell Vaccine

Download Full-text

Bi-shRNA-Furin/GM-CSF-Expressing Autologous Tumor Cell Vaccine

10.32388/mvxxgd ◽

2020 ◽

Author(s):

Keyword(s):

Cell Vaccine ◽

Autologous Tumor Cell ◽

Autologous Tumor ◽

Tumor Cell Vaccine ◽

Gm Csf ◽

Autologous Tumor Cell Vaccine

Download Full-text